Missedย NVDA?
Donโt Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities โ for free.
MDNAF Stock Forecast 2026-2027
$0.45
Current Price
$37.92M
Market Cap
Buy 4
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to MDNAF Price Targets
+785.0%
To High Target of $4.00
+619.0%
To Median Target of $3.25
+453.1%
To Low Target of $2.50
MDNAF Price Momentum
-4.3%
1 Week Change
-10.0%
1 Month Change
-45.1%
1 Year Change
-33.8%
Year-to-Date Change
-68.4%
From 52W High of $1.43
+5.4%
From 52W Low of $0.43
๐ TOP ANALYST CALLS
Did MDNAF Make This Month's Elite Buy List?
We don't follow just any analyst โ only the top 3% with a proven track record make our cut. See if Medicenna is one of their latest high-conviction picks.
Latest MDNAF Stock Price Targets & Analyst Predictions
Based on our analysis of 1 Wall Street analyst, MDNAF has a bullish consensus with a median price target of $3.25 (ranging from $2.50 to $4.00). The overall analyst rating is N/A (N/A/10). Currently trading at $0.45, the median forecast implies a 619.0% upside. This outlook is supported by 4 Buy, 0 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDNAF Analyst Ratings
4
Buy
0
Hold
0
Sell
MDNAF Price Target Range
Low
$2.50
Average
$3.25
High
$4.00
Current: $0.45
Latest MDNAF Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDNAF.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Dec 6, 2024 | HC Wainwright & Co. | Buy | Reiterates | $N/A | |
| Dec 18, 2020 | Oppenheimer | Outperform | Initiates | $N/A | |
| Dec 17, 2020 | Oppenheimer | Outperform | Initiates | $N/A | |
| Sep 10, 2020 | HC Wainwright & Co. | Buy | Initiates | $N/A |
Medicenna Therapeutics Corp. (MDNAF) Competitors
The following stocks are similar to Medicenna based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medicenna Therapeutics Corp. (MDNAF) Financial Data
Medicenna Therapeutics Corp. has a market capitalization of $37.92M with a P/E ratio of -3.0x. The company generates $0 in trailing twelve-month revenue with a 0.0% profit margin.
Revenue growth is N/A quarter-over-quarter, while maintaining an operating margin of 0.0% and return on equity of -109.8%.
Valuation Metrics
Market Cap
$37.92M
Enterprise Value
$19.86M
P/E Ratio
-3.0x
PEG Ratio
0.1x
Price/Sales
N/A
Growth & Margins
Revenue Growth (YoY)
N/A
Gross Margin
N/A
Operating Margin
0.0%
Net Margin
0.0%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+28.1%
Current Ratio
2.7x
Debt/Equity
2.2x
ROE
-109.8%
ROA
-61.6%
๐ก SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings โ tracked and updated every Monday and Thursday.
Medicenna Therapeutics Corp. (MDNAF) Business Model
About Medicenna Therapeutics Corp.
What They Do
Develops advanced immunotherapies for cancer treatment.
Business Model
Medicenna Therapeutics Corp. operates as a clinical-stage biotechnology company that generates revenue through the development of proprietary immunotherapy products, specifically its Superkine Platform. The company focuses on engineering interleukin-based therapeutics to enhance immune responses against cancer, aiming to bring innovative treatments to market through clinical trials and potential partnerships or licensing agreements.
Additional Information
The company's product pipeline includes promising candidates like MDNA11 and MDNA55, targeting various cancers and autoimmune diseases. Medicenna is committed to addressing significant unmet medical needs while emphasizing scientific rigor and patient-centered outcomes in its research and development efforts.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
18
CEO
Dr. Fahar Merchant Ph.D.
Country
Canada
IPO Year
2017
Website
www.medicenna.comMedicenna Therapeutics Corp. (MDNAF) Latest News & Analysis
Latest News
Quick Summary
Medicenna Therapeutics will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference in Toronto on April 21-22, 2026. CEO Dr. Fahar Merchant will also hold one-on-one meetings.
Why It Matters
Medicenna's participation in a key healthcare investor conference highlights its visibility and potential for investment, possibly impacting stock performance and investor interest in immunotherapy advancements.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MDNA113 is a new anti-PD-1-IL-2 Superkine targeting IL-13Rฮฑ2, designed to deliver treatment to the tumor microenvironment and enhance activation at the tumor site.
Why It Matters
MDNA113's innovative approach to targeting tumors may enhance treatment efficacy, potentially leading to increased market value for the company and impacting biotech investment strategies.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Medicenna Therapeutics (TSX: MDNA, OTCQX: MDNAF) will participate in upcoming conferences to showcase its Superkines development in cancer and autoimmune diseases, engaging with industry and investors.
Why It Matters
Medicenna's participation in key conferences highlights its progress in immunotherapy, potentially attracting investor interest and impacting stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results and Provides a Corporate Update
2 months ago
Quick Summary
Medicenna will present updated data on bizaxofusp (MDNA55) at the 7th Annual Glioblastoma Development Summit in Boston from February 17-19, 2026.
Why It Matters
Medicenna's presentation at a key summit could influence investor sentiment and stock performance, as new data on bizaxofusp may impact its market potential and future funding.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Medicenna Announces Changes to Board Composition
2 months ago
Quick Summary
Medicenna Therapeutics has appointed Richard Sutin and Angelos Georgakis to its board of directors, effective February 12, 2026. The company focuses on developing immunotherapy treatments.
Why It Matters
New board appointments at Medicenna could signal strategic shifts or enhanced governance, impacting investor confidence and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
MDNA11 showed a 50% overall response rate in 2L/3L settings and 42% post-ICI failure among 21 patients, indicating strong potential for advanced cancer treatment options.
Why It Matters
The high overall response rates (50% and 42%) for MDNA11 suggest significant efficacy in advanced cancer treatment, potentially increasing its market value and attracting investor interest.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About MDNAF Stock
What is Medicenna Therapeutics Corp.'s (MDNAF) stock forecast for 2026?
Based on our analysis of 1 Wall Street analysts, Medicenna Therapeutics Corp. (MDNAF) has a median price target of $3.25. The highest price target is $4.00 and the lowest is $2.50.
Is MDNAF stock a good investment in 2026?
According to current analyst ratings, MDNAF has 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.45. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDNAF stock?
Wall Street analysts predict MDNAF stock could reach $3.25 in the next 12 months. This represents a 619.0% increase from the current price of $0.45. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medicenna Therapeutics Corp.'s business model?
Medicenna Therapeutics Corp. operates as a clinical-stage biotechnology company that generates revenue through the development of proprietary immunotherapy products, specifically its Superkine Platform. The company focuses on engineering interleukin-based therapeutics to enhance immune responses against cancer, aiming to bring innovative treatments to market through clinical trials and potential partnerships or licensing agreements.
What is the highest forecasted price for MDNAF Medicenna Therapeutics Corp.?
The highest price target for MDNAF is $4.00 from at , which represents a 785.0% increase from the current price of $0.45.
What is the lowest forecasted price for MDNAF Medicenna Therapeutics Corp.?
The lowest price target for MDNAF is $2.50 from at , which represents a 453.1% increase from the current price of $0.45.
What is the overall MDNAF consensus from analysts for Medicenna Therapeutics Corp.?
The overall analyst consensus for MDNAF is bullish. Out of 1 Wall Street analysts, 4 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $3.25.
How accurate are MDNAF stock price projections?
Stock price projections, including those for Medicenna Therapeutics Corp., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 20, 2026 3:20 AM UTC